Generate Biomedicines (GENB) Competitors

$15.42 +0.96 (+6.64%)

Closing price 04:00 PM Eastern

Extended Trading

$15.43 +0.01 (+0.06%)

As of 05:19 PM Eastern

GENB vs. PTGX, BLTE, COGT, TERN, and APGE

Should you be buying Generate Biomedicines stock or one of its competitors? The main competitors of Generate Biomedicines include Protagonist Therapeutics (PTGX), Belite Bio (BLTE), Cogent Biosciences (COGT), Terns Pharmaceuticals (TERN), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry.

How does Generate Biomedicines compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Generate Biomedicines (NASDAQ:GENB) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

: Generate Biomedicines has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -282.83%. Generate Biomedicines' return on equity of 0.00% beat Protagonist Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Protagonist Therapeutics -282.83% -19.89% -18.40%
Generate Biomedicines N/A N/A N/A
: In the previous week, Protagonist Therapeutics had 9 more articles in the media than Generate Biomedicines. MarketBeat recorded 12 mentions for Protagonist Therapeutics and 3 mentions for Generate Biomedicines. Protagonist Therapeutics' average media sentiment score of 1.22 beat Generate Biomedicines' score of 0.37 indicating that Protagonist Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protagonist Therapeutics
7 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Generate Biomedicines
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Generate Biomedicines has lower revenue, but higher earnings than Protagonist Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Protagonist Therapeutics $46.02M 138.64 -$130.15M -$2.05 N/A
Generate Biomedicines $31.89M 61.62 N/A N/A N/A
: 98.6% of Protagonist Therapeutics shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Protagonist Therapeutics currently has a consensus target price of $108.15, suggesting a potential upside of 9.02%. Generate Biomedicines has a consensus target price of $23.20, suggesting a potential upside of 50.45%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, analysts plainly believe Generate Biomedicines is more favorable than Protagonist Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics
1 Sell rating(s)
1 Hold rating(s)

13 Buy rating(s)

0 Strong Buy rating(s)
2.80
Generate Biomedicines
0 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-282.83%	-19.89%	-18.40%
Generate Biomedicines	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	138.64	-$130.15M	-$2.05	N/A
Generate Biomedicines	$31.89M	61.62	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Protagonist Therapeutics beats Generate Biomedicines on 7 of the 12 factors compared between the two stocks.

How does Generate Biomedicines compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Generate Biomedicines (NASDAQ:GENB) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

: Generate Biomedicines' return on equity of 0.00% beat Belite Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Belite Bio N/A -19.49% -19.05%
Generate Biomedicines N/A N/A N/A
: In the previous week, Belite Bio had 8 more articles in the media than Generate Biomedicines. MarketBeat recorded 11 mentions for Belite Bio and 3 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.37 beat Belite Bio's score of 0.26 indicating that Generate Biomedicines is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Belite Bio
5 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Generate Biomedicines
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Generate Biomedicines has higher revenue and earnings than Belite Bio.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Belite Bio N/A N/A -$77.61M -$2.30 N/A
Generate Biomedicines $31.89M 61.62 N/A N/A N/A
: 0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Belite Bio currently has a consensus target price of $202.33, suggesting a potential upside of 31.06%. Generate Biomedicines has a consensus target price of $23.20, suggesting a potential upside of 50.45%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, analysts plainly believe Generate Biomedicines is more favorable than Belite Bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Belite Bio
1 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.63
Generate Biomedicines
0 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-19.49%	-19.05%
Generate Biomedicines	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Generate Biomedicines	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.30	N/A
Generate Biomedicines	$31.89M	61.62	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Generate Biomedicines beats Belite Bio on 6 of the 9 factors compared between the two stocks.

How does Generate Biomedicines compare to Cogent Biosciences?

Generate Biomedicines (NASDAQ:GENB) and Cogent Biosciences (NASDAQ:COGT) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

: Generate Biomedicines currently has a consensus price target of $23.20, suggesting a potential upside of 50.45%. Cogent Biosciences has a consensus price target of $43.45, suggesting a potential upside of 17.54%. Given Generate Biomedicines' higher probable upside, equities analysts plainly believe Generate Biomedicines is more favorable than Cogent Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Generate Biomedicines
0 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86
Cogent Biosciences
1 Sell rating(s)

2 Hold rating(s)

9 Buy rating(s)

2 Strong Buy rating(s)
2.86
: In the previous week, Cogent Biosciences had 5 more articles in the media than Generate Biomedicines. MarketBeat recorded 8 mentions for Cogent Biosciences and 3 mentions for Generate Biomedicines. Cogent Biosciences' average media sentiment score of 1.10 beat Generate Biomedicines' score of 0.37 indicating that Cogent Biosciences is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Generate Biomedicines
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cogent Biosciences
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Generate Biomedicines' return on equity of 0.00% beat Cogent Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Generate Biomedicines N/A N/A N/A
Cogent Biosciences N/A -143.09% -66.96%
: Generate Biomedicines has higher revenue and earnings than Cogent Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Generate Biomedicines $31.89M 61.62 N/A N/A N/A
Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Cogent Biosciences	N/A	-143.09%	-66.96%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89M	61.62	N/A	N/A	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Summary

Generate Biomedicines and Cogent Biosciences tied by winning 4 of the 8 factors compared between the two stocks.

How does Generate Biomedicines compare to Terns Pharmaceuticals?

Generate Biomedicines (NASDAQ:GENB) and Terns Pharmaceuticals (NASDAQ:TERN) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

: Generate Biomedicines currently has a consensus price target of $23.20, suggesting a potential upside of 50.45%. Terns Pharmaceuticals has a consensus price target of $55.14, suggesting a potential upside of 4.13%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, equities analysts plainly believe Generate Biomedicines is more favorable than Terns Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Generate Biomedicines
0 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86
Terns Pharmaceuticals
1 Sell rating(s)

10 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.27
: 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: In the previous week, Terns Pharmaceuticals had 3 more articles in the media than Generate Biomedicines. MarketBeat recorded 6 mentions for Terns Pharmaceuticals and 3 mentions for Generate Biomedicines. Terns Pharmaceuticals' average media sentiment score of 0.66 beat Generate Biomedicines' score of 0.37 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Generate Biomedicines
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Terns Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Generate Biomedicines' return on equity of 0.00% beat Terns Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Generate Biomedicines N/A N/A N/A
Terns Pharmaceuticals N/A -20.02% -19.37%
: Generate Biomedicines has higher revenue and earnings than Terns Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Generate Biomedicines $31.89M 61.62 N/A N/A N/A
Terns Pharmaceuticals N/A N/A -$96.21M -$1.03 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Terns Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Terns Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Terns Pharmaceuticals	N/A	-20.02%	-19.37%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89M	61.62	N/A	N/A	N/A
Terns Pharmaceuticals	N/A	N/A	-$96.21M	-$1.03	N/A

Summary

Generate Biomedicines beats Terns Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Generate Biomedicines compare to Apogee Therapeutics?

Generate Biomedicines (NASDAQ:GENB) and Apogee Therapeutics (NASDAQ:APGE) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

: Generate Biomedicines currently has a consensus price target of $23.20, suggesting a potential upside of 50.45%. Apogee Therapeutics has a consensus price target of $112.73, suggesting a potential upside of 35.35%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, research analysts plainly believe Generate Biomedicines is more favorable than Apogee Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Generate Biomedicines
0 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86
Apogee Therapeutics
1 Sell rating(s)

4 Hold rating(s)

11 Buy rating(s)

2 Strong Buy rating(s)
2.78
: 79.0% of Apogee Therapeutics shares are held by institutional investors. 42.8% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, Apogee Therapeutics had 4 more articles in the media than Generate Biomedicines. MarketBeat recorded 7 mentions for Apogee Therapeutics and 3 mentions for Generate Biomedicines. Apogee Therapeutics' average media sentiment score of 0.90 beat Generate Biomedicines' score of 0.37 indicating that Apogee Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Generate Biomedicines
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Apogee Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Generate Biomedicines' return on equity of 0.00% beat Apogee Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Generate Biomedicines N/A N/A N/A
Apogee Therapeutics N/A -36.77% -34.87%
: Generate Biomedicines has higher revenue and earnings than Apogee Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Generate Biomedicines $31.89M 61.62 N/A N/A N/A
Apogee Therapeutics N/A N/A -$255.84M -$4.22 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apogee Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Apogee Therapeutics	N/A	-36.77%	-34.87%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89M	61.62	N/A	N/A	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.22	N/A

Summary

Apogee Therapeutics beats Generate Biomedicines on 6 of the 11 factors compared between the two stocks.

Get Generate Biomedicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENB vs. The Competition

Export

Metric	Generate Biomedicines	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.97B	$2.90B	$4.21B	$11.87B
Dividend Yield	N/A	15.26%	5.61%	5.21%
P/E Ratio	N/A	13.16	23.40	28.47
Price / Sales	61.62	1,690.50	186.69	60.92
Price / Cash	N/A	25.75	52.82	36.52
Price / Book	N/A	3.55	38.31	6.67
Net Income	N/A	-$42.77M	$114.66M	$332.53M
7 Day Performance	23.66%	1.11%	1.23%	2.01%
1 Month Performance	12.15%	5.46%	5.54%	9.19%
1 Year Performance	N/A	19.86%	18.68%	39.59%

Generate Biomedicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENB Generate Biomedicines	N/A	$15.42 +6.6%	$23.20 +50.5%	N/A	$1.97B	$31.89M	N/A	312
PTGX Protagonist Therapeutics	1.749 of 5 stars	$98.32 -0.2%	$108.15 +10.0%	N/A	$6.29B	$46.02M	N/A	120	News Coverage Positive News Earnings Report
BLTE Belite Bio	2.9415 of 5 stars	$157.04 -3.7%	$202.33 +28.8%	N/A	$6.28B	N/A	N/A	10	Upcoming Earnings Insider Trade
COGT Cogent Biosciences	2.8911 of 5 stars	$36.73 +0.3%	$43.45 +18.3%	N/A	$6.27B	N/A	N/A	80	News Coverage Positive News Earnings Report
TERN Terns Pharmaceuticals	1.1386 of 5 stars	$52.97 +0.0%	$55.14 +4.1%	N/A	$6.11B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GENB) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Generate Biomedicines (GENB) Competitors

GENB vs. PTGX, BLTE, COGT, TERN, and APGE

How does Generate Biomedicines compare to Protagonist Therapeutics?

Summary

How does Generate Biomedicines compare to Belite Bio?

Summary

How does Generate Biomedicines compare to Cogent Biosciences?

Summary

How does Generate Biomedicines compare to Terns Pharmaceuticals?

Summary

How does Generate Biomedicines compare to Apogee Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Generate Biomedicines (GENB) Competitors

GENB vs. PTGX, BLTE, COGT, TERN, and APGE

How does Generate Biomedicines compare to Protagonist Therapeutics?

Summary

How does Generate Biomedicines compare to Belite Bio?

Summary

How does Generate Biomedicines compare to Cogent Biosciences?

Summary

How does Generate Biomedicines compare to Terns Pharmaceuticals?

Summary

How does Generate Biomedicines compare to Apogee Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools